Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Polym Sci A Polym Chem ; 55(12): 2019-2026, 2017 Jun 15.
Article in English | MEDLINE | ID: mdl-29398778

ABSTRACT

Poly(ß amino ester) polymers have received growing attention in the literature, owing to their ease of synthesis, versatile co-monomer selection, and highly tunable degradation kinetics. As such, they have shown extensive potential in many biomedical applications as well. In this work, it is demonstrated for the first time that PßAE polymers containing primary and secondary amine groups can undergo degradation by primary alcohols via transesterification mechanism. While this work emphasizes an important aspect of solvent compatibility of these networks, it also represents an interesting, simple mechanism for post synthesis drug incorporation, with riboflavin conjugation being demonstrated as a model compound.

2.
Pharm Res ; 33(3): 573-89, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26508477

ABSTRACT

PURPOSE: To develop a technique that maximizes the encapsulation of functional proteins within neutrally charged, fully PEGylated and nanoscale polymer vesicles (i.e., polymersomes). METHODS: Three conventional vesicle formation methods were utilized for encapsulation of myoglobin (Mb) in polymersomes of varying size, PEG length, and membrane thickness. Mb concentrations were monitored by UV-Vis spectroscopy, inductively coupled plasma optical emission spectroscopy (ICP-OES) and by the bicinchoninic acid (BCA) assay. Suspensions were subject to protease treatment to differentiate the amounts of surface-associated vs. encapsulated Mb. Polymersome sizes and morphologies were monitored by dynamic light scattering (DLS) and by cryogenic transmission electron microscopy (cryo-TEM), respectively. Binding and release of oxygen were measured using a Hemeox analyzer. RESULTS: Using the established "thin-film rehydration" and "direct hydration" methods, Mb was found to be largely surface-associated with negligible aqueous encapsulation within polymersome suspensions. Through iterative optimization, a novel "progressive saturation" technique was developed that greatly increased the final concentrations of Mb (from < 0.5 to > 2.0 mg/mL in solution), the final weight ratio of Mb-to-polymer that could be reproducibly obtained (from < 1 to > 4 w/w% Mb/polymer), as well as the overall efficiency of Mb encapsulation (from < 5 to > 90%). Stable vesicle morphologies were verified by cryo-TEM; the suspensions also displayed no signs of aggregate formation for > 2 weeks as assessed by DLS. "Progressive saturation" was further utilized for the encapsulation of a variety of other proteins, ranging in size from 17 to 450 kDa. CONCLUSIONS: Compared to established vesicle formation methods, "progressive saturation" increases the quantities of functional proteins that may be encapsulated in nanoscale polymersomes.


Subject(s)
Drug Carriers/chemistry , Nanoparticles/chemistry , Polymers/chemistry , Proteins/chemistry , Microscopy, Electron, Transmission/methods , Myoglobin/chemistry , Nanotechnology/methods , Particle Size , Polyethylene Glycols/chemistry , Suspensions/chemistry
3.
Biomaterials ; 34(37): 9615-22, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24016851

ABSTRACT

The biomedical use of superparamagnetic iron oxide nanoparticles has been of continued interest in the literature and clinic. Their ability to be used as contrast agents for imaging and/or responsive agents for remote actuation makes them exciting materials for a wide range of clinical applications. Recently, however, concern has arisen regarding the potential health effects of these particles. Iron oxide toxicity has been demonstrated in in vivo and in vitro models, with oxidative stress being implicated as playing a key role in this pathology. One of the key cell types implicated in this injury is the vascular endothelial cells. Here, we report on the development of a targeted polymeric antioxidant, poly(trolox ester), nanoparticle that can suppress oxidative damage. As the polymer undergoes enzymatic hydrolysis, active trolox is locally released, providing a long term protection against pro-oxidant agents. In this work, poly(trolox) nanoparticles are targeted to platelet endothelial cell adhesion molecules (PECAM-1), which are able to bind to and internalize in endothelial cells and provide localized protection against the cytotoxicity caused by iron oxide nanoparticles. These results indicate the potential of using poly(trolox ester) as a means of mitigating iron oxide toxicity, potentially expanding the clinical use and relevance of these exciting systems.


Subject(s)
Antioxidants/therapeutic use , Chromans/therapeutic use , Ferric Compounds/toxicity , Nanoparticles/toxicity , Nanoparticles/therapeutic use , Polymers/therapeutic use , Antioxidants/administration & dosage , Antioxidants/chemistry , Chromans/administration & dosage , Chromans/chemistry , Ferric Compounds/chemistry , Human Umbilical Vein Endothelial Cells , Humans , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Oxidative Stress/drug effects , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Polymers/administration & dosage , Polymers/chemistry , Reactive Oxygen Species/metabolism
4.
Acta Biomater ; 8(7): 2529-37, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22426289

ABSTRACT

Attenuation of cellular oxidative stress, which plays a central role in biomaterial-induced inflammation, provides an exciting opportunity to control the host tissue response to biomaterials. In the case of biodegradable polymers, biomaterial-induced inflammation is often a result of local accumulation of polymer degradation products, hence there is a need for new biomaterials that can inhibit this response. Antioxidant polymers, which have antioxidants incorporated into the polymer backbone, are a class of biomaterials that, upon degradation, release active antioxidants, which can scavenge free radicals and attenuate oxidative stress, resulting in improved material biocompatibility. In this work, we have synthesized poly(antioxidant ß-amino ester) (PAßAE) biodegradable hydrogels of two polyphenolic antioxidants, quercetin and curcumin. The degradation characteristics of PAßAE hydrogels and the antioxidant activity of PAßAE degradation products were studied. Treatment of endothelial cells with PAßAE degradation products protected cells from hydrogen-peroxide-induced oxidative stress.


Subject(s)
Antioxidants/pharmacology , Polymers/chemistry , Polymers/chemical synthesis , Polyphenols/pharmacology , Acrylates/chemistry , Antioxidants/administration & dosage , Cell Death/drug effects , Curcumin/chemistry , Curcumin/pharmacology , Cytoprotection/drug effects , Delayed-Action Preparations , Human Umbilical Vein Endothelial Cells , Humans , Hydrogels/chemical synthesis , Hydrogels/chemistry , Hydrogen Peroxide/pharmacology , Magnetic Resonance Spectroscopy , Oxidative Stress/drug effects , Polyphenols/administration & dosage , Quercetin/chemistry , Quercetin/pharmacology , Spectroscopy, Fourier Transform Infrared
5.
J Biomed Mater Res A ; 99(2): 184-91, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21976443

ABSTRACT

In a variety of biomedical applications (e.g., tissue engineering, drug delivery, etc.), the role of a bioactive material is to serve as a platform by which one can modulate the cellular response into a desired role. Of the methods by which one may achieve this control (e.g., shape, structure, binding, growth factor release), the control of the cellular redox state has been under evaluated. Ideally, the ability to tune the redox state of a cell provides an additional level of control over a variety of cellular responses including, cell differentiation, proliferation, and apoptosis. Yet, in order to achieve such control, it is important to know both the overall oxidative status of the cell and what molecular targets are being oxidized. In this work, poly (trolox ester) nanoparticles were evaluated for their ability to either inhibit or induce cellular oxidative stress in a dose-dependent fashion. This polymer delivery form possessed a unique ability to suppress protein oxidation, a feature not seen in the free drug form, emphasizing the advantage of the delivery/dosage formulation has upon regulating cellular response.


Subject(s)
Antioxidants/metabolism , Chromans/metabolism , Esters/metabolism , Nanoparticles/chemistry , Oxidants/chemistry , Polymers/metabolism , Antioxidants/chemistry , Antioxidants/pharmacology , Biocompatible Materials/chemistry , Biocompatible Materials/metabolism , Biocompatible Materials/pharmacology , Biomarkers/metabolism , Cells, Cultured , Chromans/chemistry , Chromans/pharmacology , Esters/chemistry , Esters/pharmacology , Human Umbilical Vein Endothelial Cells/drug effects , Humans , Materials Testing , Oxidants/metabolism , Oxidation-Reduction , Oxidative Stress , Polymers/chemistry , Polymers/pharmacology , Reactive Oxygen Species/metabolism
6.
Nanomedicine (Lond) ; 6(7): 1257-72, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21929460

ABSTRACT

Antioxidant enzymes (AOEs) catalase and superoxide dismutase (SOD) detoxify harmful reactive oxygen species, but the therapeutic utility of AOEs is hindered by inadequate delivery. AOE modification by poly-ethylene glycol (PEG) and encapsulation in PEG-coated liposomes increases the AOE bioavailability and enhances protective effects in animal models. Pluronic-based micelles formed with AOEs show even more potent protective effects. Furthermore, polymeric nanocarriers (PNCs) based on PEG-copolymers protect encapsulated AOEs from proteolysis and improve delivery to the target cells, such as the endothelium lining the vascular lumen. Antibodies to endothelial determinants conjugated to AOEs or AOE carriers provide targeting and intracellular delivery. Targeted liposomes, protein conjugates and magnetic nanoparticles deliver AOEs to sites of vascular oxidative stress in the cardiovascular, pulmonary and nervous systems. Further advances in nanodevices for AOE delivery will provide a basis for the translation of this approach in the clinical domain.


Subject(s)
Antioxidants/administration & dosage , Catalase/administration & dosage , Drug Delivery Systems/methods , Endothelium, Vascular/metabolism , Nanostructures/chemistry , Superoxide Dismutase/administration & dosage , Animals , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...